GlassScriptPhysician profile
Rasendu Jitendra Vasavada
NPI 1144260472
$9,329.47
in general payments reported to CMS, 2019-2025
48 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $888 · 2021: $1,533 · 2022: $1,656 · 2023: $1,724 · 2024: $1,872 · 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,034 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,034.48 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,525.71 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,224.82 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $866.30 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $751.31 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $558.86 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $547.64 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $461.32 | 2020-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $366.08 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $289.76 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $286.14 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $213.30 | 2020-2024 | Verquvo, Belsomra, Steglatro |
| Harmony Biosciences LLC | $194.38 | 2021-2025 | Wakix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.39 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $161.71 | 2022 | |
| Eisai INC. | $157.71 | 2020-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $152.24 | 2020-2024 | Veozah |
| Baxter Healthcare | $104.48 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $92.58 | 2024-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $82.86 | 2022-2023 | Quviviq |
| Allergan, INC. | $73.74 | 2020 | |
| Antares Pharma, INC. | $73.54 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Biohaven Pharmaceuticals, INC. | $72.50 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $63.60 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $63.03 | 2024-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $62.26 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.91 | 2021-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $57.39 | 2022-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $53.95 | 2020-2022 | |
| Exact Sciences Corporation | $52.61 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $49.59 | 2024-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $43.44 | 2024-2025 | Gemtesa |
| Avadel Cns Pharmaceuticals, LLC | $38.94 | 2024 | Lumryz |
| Jazz Pharmaceuticals INC. | $38.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $38.45 | 2023-2024 | Eliquis |
| Amarin Pharma, INC. | $36.30 | 2020-2022 | |
| Redhill Biopharma INC. | $33.51 | 2020 | |
| Esperion Therapeutics, INC. | $32.94 | 2020-2022 | |
| Halozyme INC | $31.04 | 2023 | |
| Ucb, INC. | $20.40 | 2023 | Nayzilam |
| Optinose US, INC. | $20.16 | 2024 | |
| Corium, LLC | $19.34 | 2023-2025 | Azstarys |
| Mannkind Corporation | $15.32 | 2025 | |
| Advanced Respiratory, INC | $14.80 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.73 | 2021 | |
| Depuy Synthes Sales INC. | $14.29 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.54 | 2023 | Trintellix |
| Genentech USA, INC. | $11.58 | 2020 | |
| Phathom Pharmaceuticals, INC. | $10.21 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasendu Vasavada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.